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Abstract
Endoglin (ENG, also known as CD105) is a transforming growth factor β (TGFβ) associated 
receptor and is required for both vasculogenesis and angiogenesis. Angiogenesis is important in 
the development of cerebral vasculature and in the pathogenesis of cerebral vascular diseases. 
ENG is an essential component of the endothelial nitric oxide synthase activation complex. 
Animal studies showed that ENG deficiency impairs stroke recovery. ENG deficiency also impairs 
the regulation of vascular tone, which contributes to the pathogenesis of brain arteriovenous 
malformation (bAVM) and vasospasm. In human, functional haploinsufficiency of ENG gene 
causes type I hereditary hemorrhagic telangiectasia (HHT1), an autosomal dominant disorder. 
Compared to normal population, HHT1 patients have a higher prevalence of AVM in multiple 
organs including the brain. Vessels in bAVM are fragile and tend to rupture, causing hemorrhagic 
stroke. High prevalence of pulmonary AVM in HHT1 patients are associated with a higher 
incidence of paradoxical embolism in the cerebral circulation causing ischemic brain injury. 
Therefore, HHT1 patients are at risk for both hemorrhagic and ischemic stroke. This review 
summarizes the possible mechanism of ENG in the pathogenesis of cerebrovascular diseases in 
experimental animal models and in patients.
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INTRODUCTION
In human, endoglin gene (ENG, or CD105) is located on chromosome 9q34.11. It is a type 
III transforming growth factor β (TGFβ) receptor interacting with TGFβRI (TGFβ receptor, 
type I) and/or TGFβRII (TGFβ receptor, type II)[1]. In the endothelium, ENG interacts with 
the activin receptor-like kinase 1 (ALK1 or ACVRL1), a type 1 TGFβR. ENG binds with 
TGFβ1 and TGFβ3 with high affinity in the presence of other TGFRs but not with 
TGFβ2[1–4]. ENG also binds to activin-A, bone morphogenetic protein 2 (BMP2) and 
BMP7[1]. Protein studies suggested that ENG plays an important role in modulating the 
TGFβ signaling pathway[4].
ENG gene expresses in many cell types, including endothelial cells[5, 6], activated 
monocytes and macrophages[7], mesenchymal cells, fibroblasts[8], and vascular smooth 
muscle cells [Table 1][9, 10]. Animals studies have revealed that ENG may be dispensable 
during vasculogenesis, a process from which primary capillary plexus is formed; but ENG is 
required in angiogenesis, a process that remodels the primary endothelial network into a 
mature circulatory system[11, 12]. Immunohistochemical analysis showed that in normal 
human brain, ENG is expressed in the endothelial cells of brain vessels, as well as the 
endothelial and adventitial layers of leptomeningeal arteries [Table 1][13]. ENG expression is 
upregulated in endothelial cells during wound healing and tumor vascularization, and in 
inflammatory tissues and developing embryos[1, 14, 15], indicating that ENG is an endothelial 
proliferation marker[16, 17].
Ischemic stroke is caused by occlusion of a cerebral artery. After ischemic stroke, blood 
supply to the affected brain tissue is reduced, which leads to oxygen deprivation to brain 
cells. Ischemia induces a significant increase in microvascular density, a sign of 
angiogenesis, in the penumbra of the cerebral infarct[18]. The degree of increased vessel-
density in the ischemic penumbra is positively correlated with the survival rate of stroke 
patients[19]. In addition, increased angiogenesis was associated improvement of functional 
outcome in both animal models and stroke patients[20–23].
Mutations in the ENG gene are associated with type 1 hereditary hemorrhagic telangiectasia 
(HHT)[24], also known as Osler-Rendu-Weber Syndrome. HHT is an autosomal dominant 
disease. The clinical features of HHT patients are telangiectases in mucocutaneous 
membrane and arteriovenous malformation (AVM) in multiple organs, including the skin, 
liver, lung, intestine and brain. AVMs are abnormal vessels that shunt blood directly from 
arteries to veins[25]. Brain AVM (bAVM) tends to rupture, which can cause life-threatening 
intracranial hemorrhage and hemorrhagic stroke[25]. Hemorrhage from bAVM can also 
cause long-term disability. Elevated levels of angiogenic factors including vascular 
endothelial growth factor (VEGF) were found in sporadic bAVM patients[26, 27]. High levels 
of VEGF are also associated with increase of blood-brain barrier (BBB) permeability and 
bAVM hemorrhage[27–29]. Similarly, HHT patients that have a higher incidence of AVMs in 
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multiple organs also have an increased level of plasma VEGF[30]. All of these evidence 
suggest that angiogenesis is involved in the pathogenesis of bAVM.
Since ENG plays an important role in the angiogenesis, in this review, we summarize the 
influences of ENG on endothelial function and the angiogenesis, as well as how ENG-
deficiency contributes to the pathogenesis of cerebrovascular diseases, including ischemic 
stroke and intra-cranial hemorrhage, as well as cerebrovascular malformation, stenosis and 
occlusion.
THE FUNCTION OF ENG GENE IN ANGIOGENESIS
To study the functional role of ENG in development, Eng gene knockout mice were 
generated[11, 31]. Homozygous deletion of Eng gene in mice causes embryonic death by 
E10.5–11.5[11, 31]. The endothelial cells derived from ENG deficient human embryonic stem 
cells failed to organize effectively into tubular structures in vitro[12]. VEGF induced vascular 
network was also reduced in the metatarsal bone of Eng heterozygous knockout (Eng−/−) 
mouse embryo[12]. Consistently, depletion or inhibition of ENG gene in human endothelial 
cells mitigated VEGF-induced angiogenesis[12]. These findings suggest that ENG is required 
for the differentiation and sprouting of endothelial tubes, which are important processes of 
angiogenesis.
ENG also mediates endothelial-mesenchymal communication during angiogenesis[11, 32, 33]. 
The recruitment of vascular smooth muscle cells and pericytes to newly formed vascular 
network is impaired in Eng deficient mouse embryos[11].
ENG DEFICIENCY IS AN IMPORTANT RISK FACTOR FOR BOTH 
HEMORRHAGIC AND ISCHEMIC STROKES
As mentioned in previous sections, ENG deficiency is associated with HHT1, a familial 
disease that has bAVM as one of its major phenotypes. Brain AVM contains abnormal 
vessels, that are prone to rupture, causing intracranial hemorrhage and hemorrhagic stroke. 
In addition, patients with ENG deficiency (HHT1) have a higher incidence of pulmonary 
AVM (PAVM), which is associated with a high incidence of paradoxical embolism in the 
cerebral circulation and ischemic brain injury[34]. To understand bAVM pathogenesis and to 
develop therapeutic strategies, many Eng deficient mouse models were generated. Using 
these animal models, we are able to elucidate bAVM pathogenesis and test new therapies.
Since homozygous deletion of Eng gene in mouse causes embryonic lethality[11, 31], mice 
with heterozygous deletion of Eng (Eng+/−)[31] are used to study the pathogenesis of HHT 
patients. Eng+/− mice exhibit many phenotypes that resemble those of HHT1 patients, 
including mucocutaneous telangiectases, external bleeding, and AVMs in the liver, lung, 
brain and gastrointestine[35]. Enlarged cerebrovascular structure was found in some Eng+/− 
mice with evidence of hemorrhage[35]. However, penetrance of bAVM in Eng+/− mice is 
very low, only 7%[35], suggesting that heterozygous Eng deletion alone is not sufficient to 
cause bAVM formation. In addition, the differences of the penetration of HHT phenotypes in 
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129/Ola and C57BL/6 Eng+/− mice suggests that modifier genes are contributing to the 
severity and heterogeneity of AVMs in HHT patients[35].
Based on clinical studies, we and others found that VEGF levels are increased in the plasma 
of HHT patients and in surgically resected sporadic human bAVM specimens[26, 27, 30]. The 
intensity of VEGF staining is also correlated with microvessel density in nasal mucosa from 
HHT patients[36]. Together, abnormally high level of VEGF appears to be a fundamental part 
of AVM pathophysiology[25, 30, 37–39]. Based on these studies, we overexpressed VEGF in 
the mouse brain in conjunction with Eng deletion to generate bAVM models. In adult Eng+/− 
mice, intra-brain injection of an adeno-associated viral vector expressing VEGF (AAV-
VEGF) significantly increased the penetrance of cerebrovascular abnormality[40]. Almost 
all-adult Eng+/− mice that received intra-brain injection of AAV-VEGF showed 
cerebrovascular abnormality[40]. However, unlike HHT1 patients, the vascular abnormality 
in Eng+/− mice is at the capillary level.
Bone marrow-derived cells can infiltrate into the brain angiogenic region. We found that 
macrophages are the major bone marrow-derived cells recruited to the brain angiogenic 
foci[41]. Since the accumulation of bone marrow-derived macrophage in VEGF-induced 
brain angiogenic regions peaks earlier than the increase of vessel density, macrophages 
likely play a role in angiogenesis.
Using Eng+/− mice, the influence of bone marrow derived cells in the development of bAVM 
has been studied. Transplantation of Eng+/− bone marrow to wild type mice induced vascular 
dysplasia in the brain angiogenic regions, while transplantation of wild type bone marrow to 
Eng+/− mice reduced the severity of vascular dysplasia in the brain angiogenic foci of Eng+/− 
mice[42]. These data suggested that Eng gene mutation in bone marrow cells cause vascular 
dysplasia. Importantly, these data suggested that transplantation of normal bone marrow 
cells to bAVM patients could be a therapeutic option.
Although we were able to induce vascular dysplasia in the brain of Eng+/− mice by 
overexpression of VEGF, arteriovenous shunts were not detected in these mice. Studies have 
shown that a combination of homozygous Eng inactivation and additional stimulations are 
needed for robust bAVM formation. Genetic studies also indicated that mutations of Eng 
modifier genes contribute to AVM formation[43, 44].
To avoid embryonic death caused by homozygous Eng deletion, Allinson et al.[45] generated 
an Eng-floxed (Eng2f/2f) mouse line that have the Eng gene exons 5–6 flanked by loxP sites. 
When Cre recombinase is present, the DNA sequence between the loxPsites will be deleted. 
To test whether homozygous Eng gene deletion plus angiogenic stimulation can initiate 
bAVM formation, an adeno virus expressing Cre recombinase (Ad-Cre) and AAV-VEGF 
were co-injected into the brain of Eng2f/2f mice[45, 46] to induce brain focal Eng gene 
deletion and angiogenesis. Eng2f/2f mice with focal Eng gene deletion and angiogenic 
stimulation developed vascular dysplasia beyond the capillary level around the AAV-VEGF 
injection site eight weeks after the vector injection[46]. Robust bAVM have also developed in 
the AAV-VEGF induced brain angiogenic region in mice subjected to global Eng deletion at 
the age of 8 weeks old[47]. The bAVM phenotype in these mice highly resembled the 
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phenotype of human bAVM[47]. Furthermore, Eng-null endothelial cells were found in the 
dysplastic vessels in the bAVM lesion[47]. Our studies are consistent with the studies on skin 
AVM development, and support the notion that an injury (angiogenic stimulation) is needed 
to induce bAVM.
Eng-deficient bAVM mouse models have been used to analyze the function of macrophages 
during bAVM pathogenesis. Although Eng deficiency has been shown to impair monocyte 
migration into injured tissue[48–50], an increased number of bone barrow-derived 
macrophages and activated residential microglia was found in the bAVM lesion in mouse 
and human. Compared with normal macrophages, Eng-deficient macrophages show slower 
but more persistent infiltration into the brain angiogenic regions[51]. Delayed clearance of 
macrophages and persistent inflammation could exaggerate abnormal vascular phenotypes in 
bAVM[51].
In addition to conditional knockout of Eng gene in adult mice, several cell-specific cre 
transgenic mouse lines have been used to induction of Eng deletion in specific cell-types. 
For example, the promoter of SM22α (smooth muscle actin) is used express cre in smooth 
muscle specifically. Although SM22α is predominantly expressed in smooth muscle cells in 
normal mice, Cre expression driven by the SM22α promoter in this transgenic mouse line 
was also found in other cell types, including endothelial cells[52, 53]. SM22α Cre; Eng2f/2f 
mice have Eng gene deleted in the SM22α expressing cells during the embryonic 
developmental stage. We found 90% of SM22α Cre; Eng2f/2f mice have spontaneously 
developed bAVM by 5 weeks of age and 50% of them died by 6 weeks of age[47]. BAVM 
lesions varied in size and location in these mice[47]. In addition to bAVMs, some of SM22α 
Cre; Eng2f/2f mice also developed spinal and intestinal AVMs[47]. Because AVM develops in 
this mouse line spontaneously without exogenous VEGF stimulation, this model is an ideal 
model for testing new therapeutic strategies.
As mentioned above, Eng gene not only expresses in endothelial cells[5, 6], but also 
expresses in activated monocytes/macrophages[7], mesenchymal cells, fibroblasts[8], and 
smooth muscle cells[9, 10]. Using transgenes that express cre specific cell-types, the Eng 
gene was conditionally deleted in different cell types in adult mice to determine which cell 
type is most crucial for AVM development[54, 55]. In SclCreER; Eng2f/2f mice, which have 
Eng deleted in endothelial cells only, AVM formed in the skin around the ear wound and 
back wound[54, 55]. We found that bAVM develops in the brain angiogenic region in Pdgfb-
iCreER; Eng2f/2f mice that have Eng gene deletion specifically in endothelial cells. 
Myh11Cre ER-mediated Eng deletion in smooth muscle cells in adult mice did not cause 
AVM formation in the wound area of the skin[54]. Furthermore, LysMCre; Eng2f/2f mice, 
which have Eng deleted in macrophages, did not develop AVM in any organ and in the brain 
angiogenic regions[47]. These studies indicate that Eng deletion in endothelial cells is 
essential for AVM formation in the brain and other organs[47, 54].
Eng-deficient bAVM mouse models were valuable resources to test new therapies for the 
treatment of bAVM. Current treatments for bAVM are mostly invasive and associated with 
high morbidities and mortalities[56]. Since high VEGF level is involved in the pathogenesis 
of bAVM, we have tested the feasibility of use soluble FMS-like tyrosine kinase 1 (sFLT1) 
Zhu et al. Page 5
Neuroimmunol Neuroinflamm. Author manuscript; available in PMC 2017 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
gene therapy to treat bAVM. Soluble FLT1 is an alternative transcript of FLT1 (or VEGFR1) 
containing only the extracellular domains of the receptor. Soluble FLT1 binds VEGF with 
high affinity in tissue, reduces VEGF signaling through its membrane-bound receptors, and 
thus inhibits VEGF-induced angiogenesis[14]. Systemic delivery of AAV9-sFLT1 into a 
bAVM mouse model that has Eng gene deleted globally reduced abnormal vessels in the 
bAVM region[57]. Intravenous delivery of AAV9-sFLT1 to SM22α Cre; Eng2f/2f[57] mice 
that have spontaneously developed bAVMs reduced mortality and bAVM penetrance[57]. 
This study demonstrated that mouse models are important tools to test new therapies.
HYPOXIA INDUCES ENG EXPRESSION
Hypoxia induces the expression of ENG in human and mouse brain microvascular 
endothelial cells[16, 22, 58], which ameliorates endothelial cells apoptosis regardless of the 
presence or absence of TGFβ[59]. During hypoxia stress, TGFβ induces apoptosis of 
endothelial cells[60, 61], but reduces the death of neurons[62] and vascular smooth muscle 
cells[61]. Therefore, ENG is likely to antagonize the inhibitory effects of TGFβ1 on human 
vascular endothelial cells[17, 63] and protect endothelial cells against apoptosis via TGFβ 
signaling or other independent pathways[59].
Under hypoxia conditions, ENG expression increases in many cell-types, such as, human 
microvascular endothelial cells-1 (HMEC-1) and monocytic U-937 cell. It is likely that 
hypoxia regulates ENG expression through crosstalk of several signaling pathways[58].
The transcriptional regulation of ENG expression under hypoxia condition was studied by a 
reporter assay using HeLa cells, and by the electrophoretic mobility shift assay (EMSA) 
using human umbilical cord vein endothelial cells (HUVECs). These assays confirmed the 
presence of a hypoxia response element (HRE) in the enhancer region of ENG gene[64]. 
Therefore, ENG expression can be induced by hypoxia through hypoxia-inducible factor-1 
(HIF-1). A subsequent study suggested that hypoxic induction of Eng expression in bEnd.3 
(a mouse brain endothelial cell line) cells was activated through ERK-p38 MAPK and JNK 
pathway[16], instead of HIF-1[58]. In addition, Smad3 was reported to interact with HIF 
proteins to induce the overexpression of ENG[64]. Although these studies implicated links 
among multiple factors, further studies are required to better elucidate the exact 
transcriptional regulation of ENG expression under hypoxia conditions.
ENG EXPRESSION IS UPREGULATED AFTER STROKE INJURY
Previous studies revealed that ENG was highly expressed in the penumbra region of human 
stroke lesion, where an increase of angiogenesis was found[22]. However, it was not clear at 
that time whether the angiogenesis was beneficial. In acute ischemic stroke patients, there is 
a robust mobilization of immature hematopoietic cells, colony-forming cells and long-term 
culture initiating cells[65]. It has been suggested that the degree of immature hematopoietic 
cell mobilization is directly correlated with the recovery of neurological function[66, 67]. An 
increase of ENG positive micro-particles including exosomes and shedding vesicles, which 
are small vesicles released by specific cells (endothelial or MSC)[68], were detected in 
patients’ sera collected 3 days after stroke compared to that of healthy people[69]. Certain 
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types of ENG positive micro-particles increased further in stroke patients with severe 
disability. The ENG positive micro-particles decreased gradually after the initial 
increases[69]. The number of these circulating ENG positive micro-particles was positively 
correlated with the stroke severity, even after adjusting for other demographic and clinical 
variables, such as hypotension and other stroke comorbidities[69]. Similarly, ENG positive 
circulating micro-particles released from endothelial cells were also increased in patients 
with acute ischemic stroke. The increase of ENG positive cells was positively associated 
with the severity of neurological function at hospital admission, larger brain lesion volume 
and unfavorable functional outcome at hospital discharge[70]. The increased level of 
circulating ENG positive micro-particles after acute stroke may have been caused by either 
increased circulating cells as a self-repair response to stroke or a sign of increased apoptosis 
of circulating cells in response to hypoxic conditions[69].
The role of ENG in stroke injury is complex, and is influenced by the local 
microenvironment. Constitutive expression of ENG enhances the TGFβ signaling and 
promotes new vessel wall remodeling[11]. ENG overexpression also protects against TGFβ-
induced apoptosis of endothelial cells[17, 59]. Reduction of vascular cell-apoptosis after 
hypoxia improves blood supply to ischemic tissue[58, 71]. Increase of ENG expression in 
endothelial cells could also be hazardous, because BBB permeability was increased in some 
of the capillaries that express high level of ENG, which was accompanied with mononuclear 
cell infiltration in the surrounding brain tissues[72]. These findings suggests that pronounced 
ENG overexpression might impair vessel wall integrity. Alternatively, lack of ENG 
expression may indicate severe vessel damage[72]. ENG and TGFβ are involved in the 
pathogenesis of post-ischemic brain injury in human. Abnormal ENG and TGFβfunction 
might lead to long-term neurological deterioration or cognitive disturbance after acute 
ischemic stroke[72, 73]. Homeostasis of ENG expression is crucial for maintaining normal 
angiogenesis, vascular remodeling and reduction of stoke injury.
THE EFFECT OF ENG DEFICIENCY IN ISCHEMIC STROKE INJURY
The survival of neurons in peri-infarcted regions is associated with the extent of patient 
recovery after stroke[74]. Nutrient supply supporting neuron survival is carried through 
blood. Higher microvessel density in the peri-infarct region is associated with lower 
morbidity and mortality[22]. Hypoxia-induced angiogenesis increases blood flow and oxygen 
delivery to ischemic tissues, which contributes to the recovery after stroke[28].
Angiogenesis occurs in human brain after stroke. Through examining human postmortem 
brain samples with ischemic infarcts caused by occlusive vascular diseases, capillary 
networks with regular connection and micro-vessels were found in the brain samples of 
patients who died within one week after stroke, and the neo-vasculature was in filled with 
blood in the brain samples collected from patients that died 2–3 weeks after stroke[75]. The 
micro-vessel density remains higher in the infarct area compared with the corresponding 
contralateral side three months after stroke[22]. Increased vessel density restores cerebral 
blood flow, salvages ischemic tissue, enhances neuronal survival and improves functional 
recovery of stroke survivors[76].
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ENG is expressed in proliferating vascular endothelial cells[77] and is elevated in 
inflammatory tissue and healing wound[78]. In patients, somepro-angiogenic genes, 
including Tie-2, matrix metalloproteinase-2 (MMP-2), tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1), hepatocyte growth factor-α (HGF-α) and monocyte 
chemoattractant protein-1 (MCP-1), were upregulated in ENG expressing micro-vessels in 
stroke affected tissue. These key angiogenic elements play important roles in endothelial cell 
migration, differentiation and tube-formation, as well as vessel stabilization and stem cell 
homing into the region of angiogenesis and revascularization[79].
In Eng deficient mice (Eng+/− mice), the functional performance after stroke was poorer than 
wild type animal both in the acute phase and the sub-chronic stage (one month after stroke), 
suggesting that there is an association between delayed functional recovery and Eng 
deficiency[50]. The infarct volume and atrophic volume are larger in Eng+/− mice[50]. The 
density of micro-vessels within the infarct and peri-infarct region are lower in Eng+/− mice 
than wild type mice[50, 80]. In vitro study showed that Eng+/− endothelial cells express a 
lower level of VEGF[81] compared to that of wild type endothelial cells. Eng+/− 
macrophages express lower levels of VEGF receptor 1 (VEGFR1) and 2 (VEGFR2) at the 
baseline and lower level of VEGFR2 after VEGF stimulation than wild type 
macrophages[42]. Although Eng+/− macrophages and wild type macrophages express similar 
levels of MMP9 at the baseline, unlike in wild type macrophages, the expression of MMP9 
did not increase in Eng+/− macrophages after VEGF treatment[42]. In the brain of Eng+/− 
mice, VEGF-induced upregulation of VEGFR2 expression was also impaired[82]. Together, 
these data suggest a reduced angiogenic response in the absence of normal Eng function 
may be responsible for the impairment of tissue repair in Eng deficient mice after 
experimental stroke.
In addition, our study suggested that Eng deficiency is associated with impairment of 
macrophage recruitment and clearance in the peri-infarct area during stroke recovery[50]. 
Eng expression was upregulated during the transition from monocyte to macrophage[7]. Eng 
deficiency in endothelial cell reduced adhesion and transmigration of leukocytes in response 
to ischemic injury[83]. Recruitment of monocytes to the infarcted tissue and subsequent 
vessel formation was severely impaired in HHT1 patients (who have ENG 
haploinsufficiency)[80] suggesting that ENG deficiency impairs monocyte adhesion and 
migration. In the acute phase (3 days) of stroke, Eng deficient mice had fewer macrophages 
in the peri-infarct region[50]. However, at 60 days after stroke, a time that is considered as 
recovery stage, there was an increase number of macrophage in the peri-infarct region of 
Eng deficient animals[50], suggesting a delayed homing and clearance of over-activated 
macrophage. However, the roles of post-ischemic inflammation might be bidirectional[84]. 
The inflammatory response after ischemic stroke could contribute to a secondary brain 
injury, because the influx of inflammatory cells amplifies brain cell death. On the other 
hand, inflammation also facilitated the clearance of damaged tissues and promoted tissue 
repair[85]. Therefore, the consequences of impaired macrophage in homing and clearance in 
the stroke tissue require further studied.
Interestingly, Eng+/− mice had severer brain injury than wild type mice since the first day of 
experimental stroke[50], which could not be explained by impaired tissue repair. As 
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discussed in above, hypoxia induce endothelial Eng expression, which prevents hypoxia-
induced apoptosis of endothelial cells. Therefore, vascular damage in Eng+/− mice could be 
more severe than in wild type mice after ischemic injury. In addition, Eng haploinsufficiency 
has been shown to be associated with reduced production of nitric oxide and increased 
production of superoxide under eNOS induction[86]. Nitric oxide produced by endothelial 
cell induces vascular relaxation[87]. Bioavailability of nitric oxide is lower in Eng+/− mice 
than in wild type mice[88]. Enhancing superoxide production in Eng deficient mice reduces 
vascular relaxation, and increases vessel damage and oxidative stress, all of which increases 
brain injury during the acute stage of ischemic stroke.
Since ENG plays an important role in angiogenesis and lack of ENG dampens angiogenesis, 
therapeutic stimulation of ENG could promote angiogenesis, vascular remodeling and 
improve stroke recovery, as well as reduce morbidity and mortality of stroke patients.
CIRCULATING SOLUBLE ENG MODULATES CEREBRAL VASCULAR 
REMODELING AND PLAYS ROLES IN VASOSPASM AFTER 
SUBARACHNOID HEMORRHAGE
Soluble ENG (sENG) is an alternative transcript of ENG gene, which contains only the 
extracellular domain of the full-length ENG. Soluble ENG enters the circulation in various 
conditions that related to the endothelial injury, activation, inflammation and senescence[89]. 
Our group showed that sENG level is increased in the surgical resected human bAVMs[90]. 
We have also shown that co-injection of an adenoviral vector expressing sENG with AAV-
VEGF into mouse brains caused capillary dysplasia. It is still unclear how overexpression of 
sENG causes cerebrovascular malformation. One of the possibilities is that circulating sENG 
acts as a decoy inhibiting the effect of ENG on the endothelium, leading to vascular 
malformation during angiogenesis.
Nitric oxide (NO) is a potent vascular smooth muscle relaxant, which is synthesized by the 
vascular endothelium. Eng+/− mice have a lower level of NO metabolites (nitrites) in the 
plasma and in the urine than that of wild type mice[91], suggesting that the NO level is lower 
in Eng deficient animals. The hypotensive and vasodilatory response induced by 
endothelium-dependent vasodilators was less intensive in Eng+/− mice than wild type mice. 
However, the difference of this vasodilation effect between Eng+/− mice and wild type mice 
disappeared after NO synthesis was inhibited[91]. These findings suggested that the NO level 
or the subsequent vessel response to NO is reduced in Eng+/− mice. However, after 
eliminating the endogenous NO, the vasodilatory effect induced by exogenous NO donor 
(nitroprusside) was similar in Eng+/− and wild type mice[91]. The peripheral progenitor cells 
of HHT patients expresses lower level of eNOS (endothelial nitric oxide synthase) 
mRNA[92]. Endothelial NOS produces NO in response to humoral and mechanical stimuli. 
However, resistance arteries in Eng+/− mice displayed an eNOS-dependent impairment in the 
myogenic response (normal resistance arteries contract in response to increases of perfusion 
pressure) despite of a reduced eNOS level. Eng deficient endothelial cells had uncoupled 
eNOS, which produce less NO but more superoxide[86]. Taken together, these studies 
indicate a role of Eng in the regulation of vascular tone.
Zhu et al. Page 9
Neuroimmunol Neuroinflamm. Author manuscript; available in PMC 2017 October 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Cerebral vasospasm is one of the most common complications of subarachnoid hemorrhage 
(SAH) and is associated with high morbidity and mortality. NO is found to be an important 
mediator of vasospasm[93]. The potential role of ENG on the production of NO suggests that 
ENG might be associated with vasospasm after SAH. In patients with SAH, the level of 
sENG increased in the cerebrospinal fluid (CSF) and decreased in the serum[94, 95]. In the 
subgroup with cerebral infarction due to post-SAH vasospasm, the level of sENG was higher 
in the CSF and lower in the serum than the patients who did not have post-SAH cerebral 
infarction[94, 95]. The level of sENG during the first two weeks of SAH might be a predictive 
factor for the long-term outcome, such as, 6 months after SAH[95]. Similar to sENG, the 
ENG positive endothelial micro-particles were increased in SAH patients with 
vasospasm[96].
Soluble ENG are present in both healthy people and patients with pathological conditions 
(such as preeclampsia and SAH)[89]. Several studies suggest that sENG is a naturally 
occurring antagonist of TGFβ[97]. In contrast to the lower level of sENG, the level of TGFβ1 
in the serum was higher in patients with vasospasm after SAH than those without 
vasospasm[95]. Moreover, sENG interferes the binding between TGFβ1 and its receptors[89]. 
TGFβ1 has been suggested to be involved in eNOS activation[89]. Therefore, the reduced 
sENG levels in patients with post-SAH vasospasm might reflect an impaired production of 
vasorelaxant factors, such as NO. However, there is no direct evidence supporting the cause-
and-effect relationship between vasospasm and sENG. Further studies of post-SAH 
vasospasm in Eng-deficient mice might be helpful in exploring the association of sENG and 
vasorelaxation.
Interestingly, the changes of sENG in the cerebrospinal fluid (CSF) and the serum of 
patients with SAH and vasospasm are opposite[94, 95]. In patients with Doppler sonographic 
vasospasm, the serum level of sENG was similar to those without vasospasm[95]. However, 
the serum level of sENG was reduced in patients with cerebral infarction due to severe 
vasospasm and hydrocephalus[95], suggesting that the sENG level in the serum might 
beserved as a biomarker for cerebral ischemia subsequent to vasospasm. Cerebral hypo-
perfusion or hypoxia could induce increases of focal expression of ENG and might 
contribute to the increase of sENG in the CSF of patients with vasospasm. Both 
extravasation of sENG from blood or intrathecal production of sENG could cause the 
increase of sENG in the CSF and decrease of sENG in the plasma. Further studies are 
needed to ravel the origin of sENG during post-SAH vasospasm.
Although it is not clear how ENG-positive micro-particles and sENG increased in patients 
with post-SAH vasospasm, the results of these studies indicated that, the circulating sENG is 
a promising biomarker for cerebral vasospasm after SAH.
ALTERNATIONS OF ENG EXPRESSION IN ATHEROSCLEROTIC PLAQUES 
AND STENOTIC CEREBRAL VESSELS
Carotid atherosclerotic stenosis is a major cause of ischemic stroke. As mentioned in earlier 
sections, ENG is expressed mainly in endothelial cells, smooth muscle cells and 
macrophages, which are the three major cells involved in the pathogenesis of 
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atherosclerosis[10]. The expression of ENG is very low in normal human arteries and is 
restricted to the endothelial cells of adventitial microvessels[10]. In contrast, higher ENG 
expression is present in the advanced atherosclerotic plaque of human patients[10]. The site 
of ENG expression are slightly difference between atherosclerotic plaques in carotid arteries 
and aorta. In aortic atherosclerotic plaque, ENG is predominantly expressed in smooth 
muscle cells. However, in carotid plaque, ENG is expressed in endothelial cells of neo-
vessels within the lipid core and plaque shoulders[98]. ENG expression is higher in carotid 
plaque containing higher levels of collagen and lessintra-plaque thrombi, which are 
characteristics of stable plaques[99]. These evidence indicate that ENG may promote the 
formation of intra-plaque neo-vessels and collagen and reduce the vessel leakage and 
hemorrhage. However, ENG expression in the neo-vessels of carotid atherosclerosis has also 
been found to be positively correlated with the advanced grade of plaques[100]. The distinct 
ENG expression patterns in different types of plaques suggest that ENG might play different 
roles in the course of atherogenesis progression.
Atorvastatin is a drug to treat carotid atherosclerotic plague. In a mouse model of 
atherosclerosis, atorvastatin treatment decreased the level of Eng in the serum and increased 
Eng expression in the plaque[101]. Therefore, Eng may serve as a biomarker for evaluating 
the therapeutic effect of drugs in treating atherosclerosis. More studies are needed to 
elucidate the role of ENG in the pathogenesis of atherosclerosis.
Moyamoya disease (MMD) is a rare, progressive cerebrovascular disorder caused by 
blocked arteries at the base of the brain in an area called the basal ganglia. MMD is one of 
the major causes of stroke in children and adults characterized by progressive stenosis or 
occlusion of terminal portion of internal carotid arteries and development of fragile 
collateral vessels[102]. Middle cerebral artery (MCA) of MMD patients had thicker intimal 
walls than control vessels collected from aneurysm patients[103], indicating intimal 
hyperplasia in MMD. The expression of ENG and HIF-1 are increased in the intima of 
MMD patients[103]. In addition, TGFβ3 expression was also detected, which was 
predominantly in the endothelium and was co-localized with HIF-1 and ENG[103]. Although 
the study did not find an association between cerebral blood perfusion and ENG 
expression[103], the low spatial resolution method used to evaluate the cerebral blood flow of 
the entire MCA territory might not be accurate enough to detect the real perfusion through 
the MCA branches that were used to measure the ENG expression. The increased expression 
of ENG and HIF-1 in MMD is consistent with the increased expression of ENG under 
hypoxia condition. Therefore, ENG may play roles in the pathogenesis of cerebrovascular 
stenosis or occlusion.
THE PROSPECTIVE OF MODULATING ENG EXPRESSION FOR THE 
TREATMENT OFCEREBROVASCULAR DISEASES
Since ENG has been implicated in the pathogenesis of various cerebrovascular diseases 
[Table 2], modulation of ENG expression might be a potential treatment for these 
conditions. Although currently there is no treatment available for patients with human 
cerebrovascular diseases through targeting ENG, several agents that affect ENG expression 
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specifically or non-specifically, are clinical available for treating patients or are used in 
clinical trials. TRC105 is a chimeric IgG1monoclonal antibody specifically against ENG 
that inhibits angiogenesis, induces antibody-dependent cellular cytotoxicity (ADCC) and 
apoptosis of proliferating endothelium. The safety and activity of TRC105 have been tested 
in a Phase I and a preliminary Phase II clinical trials in cancer patients[104]. Resveratrol is a 
natural component of a number of fruits, including grapes, blueberries and raspberries. The 
skin of red grapes is used to extract resveratrol. In vitro, resveratrol reduces sENG secretion 
and pro-inflammatory factors of cultured endothelial cells[105]. Therefore, it might be a 
promising non-specific inhibitor of sENG. A proper level of ENG expression might be 
crucial for maintaining normal angiogenesis and vascular remodeling in the brain. However, 
there is no report of direct regulation of ENG for treating cerebrovascular disease to date. In 
vitro study showed that statins could increase sENG secretion from endothelial cells[106]; 
and in vivo administration of stain increased Eng expression in the carotid plaque of a mouse 
model[101]. Statins are a group of medications that has been used to treat patients with 
carotid artery atherosclerosis and other ischemic cerebrovascular diseases. More studies are 
needed to test whether ENG can be used as a target for developing new therapies for the 
treatment of cerebrovascular diseases.
CONCLUSION
In summary, ENG plays a critical role in angiogenesis, vascular development and regulation 
of vascular tone. ENG deficiency is associated with the development of AVM in HHT 
patients, exacerbates stoke injury and impairs stroke recovery. ENG might be a potential 
biomarker for vasospasm after SAH and cerebrovascular stenosis. Therefore, experimental 
or therapeutic modulating of ENG expression are useful ingeneration of disease models in 
animals to study disease pathogenesis and in development of novel therapies to treat 
cerebrovascular diseases. The exact function of ENG in cerebrovascular diseases remains to 
be revealing.
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Table 1
Summary of ENG expression patterns in tissue and cell lines
Tissue Tissue samples Cell lines
Brain Humanendothelium[13]
Human adventitia[13]
Non-brain Human placenta[6] HUVEC[5]
Human spleen[7] HOON[6]
Murine ovary and uterus[8] U-937[6, 7]
Murine heart[8] HL- 60 [7]
Murine muscle[8] Cultured monocytes[7]
Murine placenta[8] NCTC-2071[8]
Murine spleen[8] VSMC[9]
HASMC[10]
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